Fidelity Investments’s Allogene Therapeutics ALLO Stock Holding History

Fidelity Investments’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25M	Buy	12,009,043 +10,419,213	+655%	+$22.9M	﹤0.01%	1800
2026 Q1	$3.88M	Buy	1,589,830 +144,069	+10%	+$289K	﹤0.01%	2394
2025 Q4	$1.98M	Buy	1,445,761 +734,801	+103%	+$969K	﹤0.01%	2622
2025 Q3	$882K	Sell	710,960 -272,041	-28%	-$324K	﹤0.01%	2832
2025 Q2	$1.11M	Sell	983,001 -6,411,161	-87%	-$8.52M	﹤0.01%	2683
2025 Q1	$10.8M	Sell	7,394,162 -16,377,833	-69%	-$30.9M	﹤0.01%	1882
2024 Q4	$50.6M	Sell	23,771,995 -6,254,961	-21%	-$15.4M	﹤0.01%	1376
2024 Q3	$84.1M	Sell	30,026,956 -1,230,644	-4%	-$3.28M	0.01%	1173
2024 Q2	$72.8M	Buy	31,257,600 +5,893,802	+23%	+$17.4M	﹤0.01%	1164
2024 Q1	$113M	Buy	25,363,798 +122,299	+0.5%	+$510K	0.01%	1005
2023 Q4	$81M	Buy	25,241,499 +97,568	+0.4%	+$277K	0.01%	1094
2023 Q3	$79.7M	Buy	25,143,931 +225,976	+0.9%	+$990K	0.01%	1066
2023 Q2	$124M	Buy	24,917,955 +23,548,101	+1,719%	+$127M	0.01%	902
2023 Q1	$6.77M	Sell	1,369,854 -187,877	-12%	-$1.2M	﹤0.01%	2009
2022 Q4	$9.8M	Buy	1,557,731 +328,073	+27%	+$3.04M	﹤0.01%	1901
2022 Q3	$13.3M	Sell	1,229,658 -91,236	-7%	-$1.24M	﹤0.01%	1778
2022 Q2	$15.1M	Buy	1,320,894 +197,226	+18%	+$1.75M	﹤0.01%	1775
2022 Q1	$10.2M	Sell	1,123,668 -751,808	-40%	-$7.83M	﹤0.01%	2114
2021 Q4	$28M	Buy	1,875,476 +966,226	+106%	+$17M	﹤0.01%	1663
2021 Q3	$23.4M	Buy	909,250 +245,401	+37%	+$5.83M	﹤0.01%	1768
2021 Q2	$17.3M	Buy	663,849 +98,358	+17%	+$2.8M	﹤0.01%	1899
2021 Q1	$20M	Buy	565,491 +69	+0%	+$2.33K	﹤0.01%	1806
2020 Q4	$14.3M	Sell	565,422 -732,429	-56%	-$23.9M	﹤0.01%	1845
2020 Q3	$48.9M	Sell	1,297,851 -1,614,626	-55%	-$60.9M	﹤0.01%	1202
2020 Q2	$125M	Sell	2,912,477 -658,435	-18%	-$23.8M	0.01%	790
2020 Q1	$69.4M	Sell	3,570,912 -1,290,054	-27%	-$30.7M	0.01%	905
2019 Q4	$126M	Sell	4,860,966 -670,918	-12%	-$18.5M	0.01%	829
2019 Q3	$151M	Sell	5,531,884 -101,049	-2%	-$2.88M	0.02%	734
2019 Q2	$151M	Sell	5,632,933 -567,610	-9%	-$15.8M	0.02%	750
2019 Q1	$178M	Buy	6,200,543 +1,289,556	+26%	+$37.4M	0.02%	684
2018 Q4	$130M	Buy	+4,910,987	New	+$130M	0.02%	737

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments's ALLO Position: Q2 2026 in Review

Fidelity Investments increased its Allogene Therapeutics (ALLO) stake by 655% in Q2 2026, buying an estimated $22.9M and bringing the position to 12,009,043 shares worth $25M. The position accounts for ﹤0.01% of the portfolio, ranked #1800.

Fidelity Investments first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $178M in Q1 2019. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Fidelity Investments held 12,009,043 shares of Allogene Therapeutics worth $25M as of Q2 2026.
Fidelity Investments bought 10,419,213 Allogene Therapeutics shares in Q2 2026, an estimated $22.9M.
Allogene Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1800 holding.
Fidelity Investments first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
Fidelity Investments's Allogene Therapeutics position peaked at $178M in Q1 2019.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.